Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsPaul Feuerstadt, MD, FACG, AGAF
Associate Clinical ProfessorAbout
Copy Link
Biography
A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude.
Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, New York for his clinical fellowship training.
Throughout Dr. Feuerstadt’s training and practice he has been actively involved in research and other academic pursuits. His areas of interest include chronic diarrheal syndromes with a specific focus on Clostridiodes difficile infection, irritable bowel syndrome (IBS) and ischemic diseases of the gut. He has presented his research extensively at national meetings and has authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally. Dr. Feuerstadt founded a website entitled "Everythingcdifficile.com" as an educational resource for patients and providers about this infectious disease. Finally, he is passionate about mentoring the fellows in the Division of Digestive Disease at Yale-New Haven Hospital where he holds a clinical appointment as an Assistant Clinical Professor of Medicine.
His clinical practice is his ultimate passion filling the majority of his work time as he sees a broad spectrum of patients with gastrointestinal and hepatic disease. Dr. Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital.
Appointments
Digestive Diseases
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Montefiore Medical Center-Albert Einstein College of Medicine (2010)
- Categorical Resident
- New York Presbyterian Hospital-Weill Cornell Medical Center (2007)
- MD
- Weill Cornell Medical College (2004)
- BA
- University of Pennsylvania (2000)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-7643-9576
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Kanika Sehgal, MBBS
Treatment Outcome
Publications
2025
Multi-Species Synbiotic Supplementation Enhances Gut Microbial Diversity, Increases Urolithin A and Butyrate Production, and Reduces Inflammation in Healthy Adults: A Randomized, Placebo-Controlled Trial
Napier B, Allegretti J, Feuerstadt P, Kelly C, Van Hise N, Jäger R, Kassam Z, Reid G. Multi-Species Synbiotic Supplementation Enhances Gut Microbial Diversity, Increases Urolithin A and Butyrate Production, and Reduces Inflammation in Healthy Adults: A Randomized, Placebo-Controlled Trial. Nutrients 2025, 17: 2734. PMID: 40944126, PMCID: PMC12430871, DOI: 10.3390/nu17172734.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPlacebo-controlled trialBiological functionsButyrate levelsButyrate-producing speciesGut microbial diversitySystemic inflammationFecal microbiome compositionFecal butyrate levelsMicrobiome-derived metabolitesUrolithin AButyrate producersAlpha diversityMicrobial diversityBeneficial microbesPrecursor metabolismProbiotic strainsButyrate productionMicrobiome compositionHealthy adultsBaseline day 0Fecal butyrateEnd-of-studyPlacebo-ControlledProbiotic supplementationSerum CRPMaking Sense of Differing Guidelines for Clostridioides difficile Infection
Sehgal K, Feuerstadt P, Wilcox M. Making Sense of Differing Guidelines for Clostridioides difficile Infection. Infectious Disease Clinics Of North America 2025 PMID: 40796471, DOI: 10.1016/j.idc.2025.07.010.Peer-Reviewed Original ResearchAltmetricSafety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome
Aroniadis O, Guthmueller B, Dehlin K, Srivastava S, Feuerstadt P, Lembo A, Weber H. Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome. Infectious Diseases And Therapy 2025, 14: 2157-2169. PMID: 40784972, PMCID: PMC12425869, DOI: 10.1007/s40121-025-01208-0.Peer-Reviewed Original ResearchCitationsConceptsTreatment-emergent adverse eventsConcurrent IBSStandard-of-careIrritable bowel syndromeSustained clinical responseExploratory subgroup analysisClinical responsePrimary endpointAntibiotic treatmentSerious treatment-emergent adverse eventsTreatment successBowel syndromeRecurrent ClostridioidesOpen-labelCDI recurrenceSingle-doseSecondary endpointsFecal microbiotaEfficacious optionAdverse eventsProspective studyIntroductionThe safetySubgroup analysisFDA approvalRCDIAssessment of real-world disease severity in patients with eosinophilic esophagitis in the United States
Dellon E, Furuta G, Feuerstadt P, Bansal P, Totev T, Patterson-Lomba O, Wang H, Sundaresan S, Ayyagari R, Fan T, Jiang J, Boules M, Terreri B. Assessment of real-world disease severity in patients with eosinophilic esophagitis in the United States. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251347361. PMID: 40583970, PMCID: PMC12202916, DOI: 10.1177/17562848251347361.Peer-Reviewed Original ResearchAltmetricConceptsHealthcare resource utilizationDisease severityEosinophilic esophagitisChart reviewTreatment patternsTreatment linesReview of medical recordsChart review of medical recordsDiagnosis of EoE.Diagnosis of EoEStudy outcomesAllergic comorbiditiesPatient demographicsEoEPatientsMedical recordsSevere diseaseClinical practicePost-hocEsophagealSeveritySymptomsDiseaseTreatmentDiagnostic processSu2014: HETEROGENEITY IN RANDOMIZED CONTROLLED TRIALS OF FECAL MICROBITA TRANSPLANTATION FOR IRRITABLE BOWEL SYNDROME
Sehgal K, Patel S, Chaar A, Feuerstadt P. Su2014: HETEROGENEITY IN RANDOMIZED CONTROLLED TRIALS OF FECAL MICROBITA TRANSPLANTATION FOR IRRITABLE BOWEL SYNDROME. Gastroenterology 2025, 169: s-931. DOI: 10.1016/s0016-5085(25)03075-6.Peer-Reviewed Original ResearchConceptsTu1777: OUTCOMES OF UNDERWEIGHT PATIENTS WITH COLONIC ISCHEMIA
Sehgal K, Patel S, Chaar A, Bhutta A, Fenster M, Brandt L, Feuerstadt P. Tu1777: OUTCOMES OF UNDERWEIGHT PATIENTS WITH COLONIC ISCHEMIA. Gastroenterology 2025, 169: s-1486. DOI: 10.1016/s0016-5085(25)04306-9.Peer-Reviewed Original ResearchSa1938: PHYSICIAN EXPERIENCES AND USABILITY OF FECAL MICROBIOTA, LIVE-JSLM (RBL) ADMINISTERED VIA COLONOSCOPY TO ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: ANALYSIS OF A PHASE 3B STUDY
Khanna S, Awad T, Guthmueller B, Feuerstadt P, Yoho D, Van Handel D, Gonthier M, Clark B. Sa1938: PHYSICIAN EXPERIENCES AND USABILITY OF FECAL MICROBIOTA, LIVE-JSLM (RBL) ADMINISTERED VIA COLONOSCOPY TO ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: ANALYSIS OF A PHASE 3B STUDY. Gastroenterology 2025, 169: s-592. DOI: 10.1016/s0016-5085(25)02300-5.Peer-Reviewed Original Research119: CDI-SCOPE: A PHASE 3B MULTI-CENTER, SINGLE-ARM TRIAL EXPLORING THE SAFETY AND EFFECTIVENESS OF FECAL MICROBIOTA, LIVE-JSLM ADMINISTERED BY COLONOSCOPY TO ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
Khanna S, Feuerstadt P, Awad T, Guthmueller B, Armandi D, Clark B. 119: CDI-SCOPE: A PHASE 3B MULTI-CENTER, SINGLE-ARM TRIAL EXPLORING THE SAFETY AND EFFECTIVENESS OF FECAL MICROBIOTA, LIVE-JSLM ADMINISTERED BY COLONOSCOPY TO ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION. Gastroenterology 2025, 169: s-33. DOI: 10.1016/s0016-5085(25)01036-4.Peer-Reviewed Original ResearchSa1940: SAFETY OF FECAL MICROBIOTA, LIVE-JSLM, IN ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: AN INTEGRATED SAFETY ANALYSIS FROM 5 PROSPECTIVE CLINICAL TRIALS
Lee C, Feuerstadt P, Louie T, Bancke L, Guthmueller B, Harvey A, Hoeyer F, Alonso C, Allegretti J, Orenstein R, Dubberke E, Khanna S. Sa1940: SAFETY OF FECAL MICROBIOTA, LIVE-JSLM, IN ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: AN INTEGRATED SAFETY ANALYSIS FROM 5 PROSPECTIVE CLINICAL TRIALS. Gastroenterology 2025, 169: s-592-s-593. DOI: 10.1016/s0016-5085(25)02302-9.Peer-Reviewed Original ResearchSa1939: HEALTH-RELATED QUALITY OF LIFE IS CORRELATED WITH MICROBIOME AND METABOLOME COMPOSITIONS DURING TREATMENT FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: EXPLORATORY ANALYSIS OF A PHASE 3 STUDY OF FECAL MICROBIOTA, LIVE-JSLM
Mishra R, Harvey A, Guo A, Tillotson G, Feuerstadt P, Khanna S, Louie T, Elliott S, Lee C, Shannon W, Blount K. Sa1939: HEALTH-RELATED QUALITY OF LIFE IS CORRELATED WITH MICROBIOME AND METABOLOME COMPOSITIONS DURING TREATMENT FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: EXPLORATORY ANALYSIS OF A PHASE 3 STUDY OF FECAL MICROBIOTA, LIVE-JSLM. Gastroenterology 2025, 169: s-592. DOI: 10.1016/s0016-5085(25)02301-7.Peer-Reviewed Original Research
News
Copy Link
News
- November 06, 2025Source: HCPLive
Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD
- February 18, 2025
Voluntary Faculty Awards Honor Outstanding Educators
- August 29, 2024Source: LiveScience.com
For C. diff, antibiotic resistance comes at a cost
- May 01, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (May 2024)